Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide in Prolactinomas Beyond Dopamine Agonist Therapy
NCT06295952Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in prolactinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2024; status: recruiting.
02
Drugs
pasireotide LAR
03
Conditions
prolactinoma
Beyond the preview
Go deeper on NCT06295952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06295952.